MedTrace Logo

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

NCT05174156 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-07-14

No results posted yet for this study

Summary

This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS) and multiple immunohistochemistry (mIHC) for the treatment of SHR-1210 in combination with paclitaxel and platinum in advanced esophageal cancer.

Conditions

  • Advanced Esophageal Cancer

Interventions

DRUG

Combination therapy

SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin

Sponsors & Collaborators

  • Nanjing Geneseeq Technology Inc.

    collaborator INDUSTRY

  • Jiangsu HengRui Medicine Co., Ltd.

    collaborator INDUSTRY

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05174156 on ClinicalTrials.gov